Astellas Pharma Inc. (ALPMY)
Astellas Pharma Statistics
Share Statistics
Astellas Pharma has 1.79B shares outstanding. The number of shares has increased by -0.17% in one year.
| Shares Outstanding | 1.79B |
| Shares Change (YoY) | -0.17% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.79B |
| Failed to Deliver (FTD) Shares | 14.9K |
| FTD / Avg. Volume | 6.94% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 171.73 and the forward PE ratio is null. Astellas Pharma's PEG ratio is -2.08.
| PE Ratio | 171.73 |
| Forward PE | n/a |
| PS Ratio | 1.83 |
| Forward PS | null |
| PB Ratio | 1.83 |
| P/FCF Ratio | 32.53 |
| PEG Ratio | -2.08 |
Enterprise Valuation
Astellas Pharma has an Enterprise Value (EV) of 3,511.5B.
| EV / Sales | 2.19 |
| EV / EBITDA | 18.03 |
| EV / EBIT | 20.36 |
| EV / FCF | 39.03 |
Financial Position
The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.58.
| Current Ratio | 0.93 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | 4.72 |
| Debt / FCF | 10.22 |
| Interest Coverage | 2.13 |
Financial Efficiency
Return on Equity is 1.07% and Return on Invested Capital is 0.63%.
| Return on Equity | 1.07% |
| Return on Assets | 0.48% |
| Return on Invested Capital | 0.63% |
| Revenue Per Employee | $108.69M |
| Profits Per Employee | $1.16M |
| Employee Count | 14,754 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 1.18 |
Taxes
| Income Tax | 7.92B |
| Effective Tax Rate | 31.74% |
Stock Price Statistics
The stock price has increased by -1.68% in the last 52 weeks. The beta is 0.17, so Astellas Pharma's price volatility has been higher than the market average.
| Beta | 0.17 |
| 52-Week Price Change | -1.68% |
| 50-Day Moving Average | 9.62 |
| 200-Day Moving Average | 10.59 |
| Relative Strength Index (RSI) | 50.2 |
| Average Volume (20 Days) | 214.61K |
Income Statement
In the last 12 months, Astellas Pharma had revenue of 1,603.7B and earned 17.05B in profits. Earnings per share was 9.51.
| Revenue | 1,603.7B |
| Gross Profit | 1,311.2B |
| Operating Income | 25.52B |
| Net Income | 17.05B |
| EBITDA | 194.81B |
| EBIT | 36.97B |
| Earnings Per Share (EPS) | 9.51 |
Balance Sheet
The company has 335.69B in cash and 920.02B in debt, giving a net cash position of -584.33B.
| Cash & Cash Equivalents | 335.69B |
| Total Debt | 920.02B |
| Net Cash | -584.33B |
| Retained Earnings | 809.4B |
| Total Assets | 3,735.5B |
| Working Capital | -133.15B |
Cash Flow
In the last 12 months, operating cash flow was 172.47B and capital expenditures -82.5B, giving a free cash flow of 89.98B.
| Operating Cash Flow | 172.47B |
| Capital Expenditures | -82.5B |
| Free Cash Flow | 89.98B |
| FCF Per Share | 50.2 |
Margins
Gross margin is 81.76%, with operating and profit margins of 1.59% and 1.06%.
| Gross Margin | 81.76% |
| Operating Margin | 1.59% |
| Pretax Margin | 1.56% |
| Profit Margin | 1.06% |
| EBITDA Margin | 12.15% |
| EBIT Margin | 1.59% |
| FCF Margin | 5.61% |
Dividends & Yields
ALPMY pays an annual dividend of $0.48, which amounts to a dividend yield of 2.3%.
| Dividend Per Share | $0.48 |
| Dividend Yield | 2.3% |
| Dividend Growth (YoY) | 11.84% |
| Payout Ratio | -216.87% |
| Earnings Yield | 0.58% |
| FCF Yield | 3.07% |
Analyst Forecast
Currently there are no analyst rating for ALPMY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Apr 2, 2014. It was a forward split with a ratio of 5:4.
| Last Split Date | Apr 2, 2014 |
| Split Type | forward |
| Split Ratio | 5:4 |
Scores
| Altman Z-Score | 0.74 |
| Piotroski F-Score | 5 |